OrgUnit's Researchers
(Persons)

Results 1-5 of 20 (Search time: 0.002 seconds).

FullnameTranslated NameEmail
Baker, AmyAmy.BAKER@austin.org.au
Balasubramanian, Adithyaadithya.balasubramanian@austin.org.au
Burgess, Adele NAdele.BURGESS@austin.org.au
Cher, Lawrence MLawrence.CHER@austin.org.au
Fancourt, TinekeTineke.FANCOURT@austin.org.au

OrgUnit's Researchers publications
(Dept/Workgroup Publication)

Results 141-160 of 548 (Search time: 0.01 seconds).

Publication YearTitleAuthor(s)
141Dec-2021Developments in systemic therapies for the management of lung cancer.Heynemann, Sarah; Mitchell, Paul L R 
1427-Sep-2018Differences in cancer survival by sex: a population-based study using cancer registry data.Afshar, Nina; English, Dallas R; Thursfield, Vicky; Mitchell, Paul L R ; Te Marvelde, Luc; Farrugia, Helen; Giles, Graham G; Milne, Roger L
14318-Oct-2016Digital PCR of genomic rearrangements for monitoring circulating tumour DNADo, Hongdo; Cameron, Daniel; Molania, Ramyar; Thapa, Bibhusal ; Rivall, Gareth; Mitchell, Paul L R ; Murone, Carmel ; John, Thomas ; Papenfuss, Anthony; Dobrovic, Alexander 
41-Jun-2006Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Nicholaou, Theo; Ebert, Lisa; Davis, Ian D; Robson, Neil; Klein, Oliver ; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan S 
5Nov-2021Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study.Mazza, Danielle; Lin, Xiaoping; Walter, Fiona M; Young, Jane M; Barnes, David J; Mitchell, Paul L R ; Brijnath, Bianca; Martin, Andrew; O'Byrne, Kenneth J; Emery, Jon D
614-Feb-2013Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.Tebbutt, Niall C ; Parry, M M; Zannino, D; Strickland, A H; Van Hazel, G A; Pavlakis, N; Ganju, V; Mellor, D; Dobrovic, Alexander ; Gebski, V J
714-Aug-2015Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.Chan, David L; Pavlakis, Nick; Shapiro, Jeremy; Price, Timothy J; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva
829-Jan-2021Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study.Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C 
915-Apr-2021Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy J; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C 
1022-Sep-2023Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour.Klein, Oliver ; Palmer, Jodie ; Behren, Andreas; Cebon, Jonathan S ; Kee, Damien 
11Apr-2020Durvalumab induced sarcoid-like pulmonary lymphadenopathy.Sanderson, Emma ; Wimaleswaran, Hari ; Senko, Clare ; White, Shane ; McDonald, Christine F 
12Sep-2020Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.Nowak, Anna K; Lesterhuis, W Joost; Kok, Peey-Sei; Brown, Chris; Hughes, Brett Gm; Karikios, Deme J; John, Thomas ; Kao, Steven C-H; Leslie, Connull; Cook, Alistair M; Pavlakis, Nick; Briscoe, Karen; O'Byrne, Kenneth J; Karapetis, Christos S; Lam, Wei-Sen; Langford, Ailsa; Yip, Sonia; Stockler, Martin R
1329-Jan-2018DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.Tögel, Lars; Nightingale, Rebecca; Wu, Rui; Chüeh, Anderly C; Al-Obaidi, Sheren; Luk, Ian; Dávalos-Salas, Mercedes; Chionh, Fiona; Murone, Carmel ; Buchanan, Daniel D; Chatterton, Zac; Sieber, Oliver M; Arango, Diego; Tebbutt, Niall C ; Williams, David; Dhillon, Amardeep S; Mariadason, John M 
1423-Sep-2019Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.Leal, Mariana F; Haynes, Benjamin P; Schuster, Eugene F; Yeo, Belinda ; Afentakis, Maria; Zabaglo, Lila; Martins, Vera; Buus, Richard; Dodson, Andrew; Cheang, Maggie C U; Smith, Ian E; Martin, Lesley-Ann; Dowsett, Mitch
152019Ectopic breast cancer in the inguinal region.Loh, Zoe ; Yeo, Belinda ; Williams, David S ; Gyorki, David E
162023Editorial: Overcoming drug relapse and therapy resistance in NSCLC.Parakh, Sagun ; Leong, Tracy L ; Best, Sarah A; Poh, Ashleigh R
172019Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.Tiu, Crescens; Loh, Zoe ; Gan, Chun Loo; Gan, Hui K ; John, Thomas ; Hawkes, Eliza A 
182019The effects of adjuvant endocrine therapy on bone health in women with breast cancer.Ramchand, Sabashini K ; Cheung, Yee-Ming Melody ; Yeo, Belinda ; Grossmann, Mathis 
191-Jul-2023Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.Cheung, Yee-Ming M; Hoermann, Rudolf; Van, Karen; Wu, Damian; Healy, Jenny; Halim, Bella; Raval, Manjri ; McGill, Maria; Al-Fiadh, Ali; Chao, Michael ; White, Shane ; Yeo, Belinda ; Zajac, Jeffrey D ; Grossmann, Mathis 
2022-Oct-2022Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.Cheung, Yee-Ming M; Hoermann, Rudolf; Van, Karen; Wu, Damian; Healy, Jenny; Chao, Michael ; White, Shane ; Yeo, Belinda ; Zajac, Jeffrey D ; Grossmann, Mathis